MX2010006893A - Derivados de benzotiazol y benzoxazol y metodos de uso. - Google Patents

Derivados de benzotiazol y benzoxazol y metodos de uso.

Info

Publication number
MX2010006893A
MX2010006893A MX2010006893A MX2010006893A MX2010006893A MX 2010006893 A MX2010006893 A MX 2010006893A MX 2010006893 A MX2010006893 A MX 2010006893A MX 2010006893 A MX2010006893 A MX 2010006893A MX 2010006893 A MX2010006893 A MX 2010006893A
Authority
MX
Mexico
Prior art keywords
methods
benzothiazole
compounds
benzoxazole derivatives
formula
Prior art date
Application number
MX2010006893A
Other languages
English (en)
Inventor
Robert J Altenbach
Lawrence A Black
Marlon D Cowart
Gregory A Gfesser
Chen Zhao
Brian D Wakefield
Huaqinq Liu
Gin C Hsieh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2010006893A publication Critical patent/MX2010006893A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)

Abstract

Se describen compuestos de la fórmula (I) que son útiles para tratar condiciones o trastornos evitados mediante o mejorados mediante ligandos del receptor histamina-3. También se describen composiciones farmacéuticas de los compuestos de la fórmula (I), métodos para utilizar dichos compuestos y composiciones, y un procedimiento para preparar los compuestos.
MX2010006893A 2007-12-20 2008-12-18 Derivados de benzotiazol y benzoxazol y metodos de uso. MX2010006893A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1551307P 2007-12-20 2007-12-20
US12/337,433 US8153813B2 (en) 2007-12-20 2008-12-17 Benzothiazole and benzooxazole derivatives and methods of use
PCT/US2008/087413 WO2009085945A1 (en) 2007-12-20 2008-12-18 Benzothiazole and benzoxazole derivatives and methods of use

Publications (1)

Publication Number Publication Date
MX2010006893A true MX2010006893A (es) 2010-10-05

Family

ID=40789367

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006893A MX2010006893A (es) 2007-12-20 2008-12-18 Derivados de benzotiazol y benzoxazol y metodos de uso.

Country Status (14)

Country Link
US (2) US8153813B2 (es)
EP (1) EP2237779A1 (es)
JP (1) JP2011507884A (es)
KR (1) KR20100103630A (es)
CN (1) CN101951904A (es)
AU (1) AU2008343115A1 (es)
BR (1) BRPI0821285A2 (es)
CA (1) CA2709961A1 (es)
IL (1) IL206476A0 (es)
MX (1) MX2010006893A (es)
NZ (1) NZ586301A (es)
RU (1) RU2010130175A (es)
WO (1) WO2009085945A1 (es)
ZA (1) ZA201004689B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808773A (en) 2006-06-23 2008-02-16 Abbott Lab Cyclopropyl amine derivatives
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
EP2566864B1 (en) * 2010-05-07 2014-09-03 Boehringer Ingelheim International GmbH Pyridazinones as gpr119 agonists
CN103153062B (zh) 2010-05-24 2015-07-15 因特利凯有限责任公司 杂环化合物及其用途
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
PT2766359T (pt) 2011-10-14 2016-07-14 Ambit Biosciences Corp Compostos heterocíclicos e utilização dos mesmos como moduladores de recetores tirosina-cinase de tipo iii
WO2013076590A1 (en) 2011-11-23 2013-05-30 Oxygen Healthcare Research Pvt. Ltd Benzothiazine compounds as h3 receptor ligands
CA2872110C (en) * 2012-07-18 2019-08-06 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
CN102911135B (zh) * 2012-10-18 2016-01-13 内蒙古工业大学 2-巯基苯并噻唑类衍生物的合成方法
FR3003466B1 (fr) * 2013-03-22 2015-08-07 Servier Lab Utilisation du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide pour le traitement des douleurs neuropathiques
EA035646B1 (ru) 2014-08-29 2020-07-21 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
EA201790408A1 (ru) 2014-08-29 2017-09-29 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
MX2017016908A (es) * 2015-06-22 2018-08-15 Actelion Pharmaceuticals Ltd Inhibidores de nadph oxidasa 4.
EP3848035A1 (en) 2015-12-10 2021-07-14 PTC Therapeutics, Inc. 1,4-disubstituted pyridazine compounds for treating huntington's disease
AU2017231781C1 (en) * 2016-03-11 2021-12-16 Ac Immune Sa Bicyclic compounds for diagnosis and therapy
CN107141282B (zh) * 2017-03-29 2019-11-05 重庆文理学院 一种苯并咪唑杂氮环丁酮衍生物及其在抗肿瘤药物中的应用
SG11201911615WA (en) 2017-06-05 2020-01-30 Ptc Therapeutics Inc Compounds for treating huntington's disease
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
CN108250194A (zh) * 2018-02-12 2018-07-06 李化绪 一种二氟苯并噻唑类化合物及其在降血脂药物中的应用
WO2019191092A1 (en) 2018-03-27 2019-10-03 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
CA3104516A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
JP7421507B2 (ja) 2018-06-27 2024-01-24 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
US11355713B2 (en) 2019-06-24 2022-06-07 Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd. Hole transport material, manufacturing method thereof, and electroluminescent device thereof
CN110299460B (zh) * 2019-06-24 2020-11-24 武汉华星光电半导体显示技术有限公司 一种空穴传输材料、制备方法及电致发光器件

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654296A (en) * 1969-01-10 1972-04-04 Merck & Co Inc 2-chlorobenzothiazolecarboxamides
JP2869561B2 (ja) 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
DE60120881T2 (de) 2000-04-07 2007-01-18 Samsung Electronics Co., Ltd., Suwon Sulfonamide als matrix-metalloproteinase inhibitoren
MXPA05005116A (es) 2002-11-12 2005-07-01 Abbott Lab Aminas biciclicas sustituidas en la forma de ligandos del receptor de histamina-3.
US20040224952A1 (en) * 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
AU2005260955A1 (en) * 2004-07-14 2006-01-19 Astellas Pharma Inc. Agent for promoting the recovery from dysfunction after the onset of central neurological disease
DE602005009021D1 (de) 2004-12-17 2008-09-25 Lilly Co Eli Neue mch-rezeptorantagonisten
EP1707204A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands
EP1707203A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EP2298734A3 (en) * 2005-06-03 2011-07-13 Abbott Laboratories Cyclobutyl amine derivatives
US7576110B2 (en) 2005-09-22 2009-08-18 Abbott Laboratories Benzothiazole cyclobutyl amine derivatives
KR101280333B1 (ko) * 2006-03-28 2013-07-02 하이 포인트 파마슈티칼스, 엘엘씨 히스타민 ｈ３ 수용체 활성을 갖는 벤조티아졸
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use

Also Published As

Publication number Publication date
IL206476A0 (en) 2010-12-30
EP2237779A1 (en) 2010-10-13
US20120164070A1 (en) 2012-06-28
US8153813B2 (en) 2012-04-10
WO2009085945A1 (en) 2009-07-09
CA2709961A1 (en) 2009-07-09
CN101951904A (zh) 2011-01-19
JP2011507884A (ja) 2011-03-10
ZA201004689B (en) 2011-03-30
US20090163464A1 (en) 2009-06-25
KR20100103630A (ko) 2010-09-27
AU2008343115A1 (en) 2009-07-09
BRPI0821285A2 (pt) 2017-06-13
NZ586301A (en) 2012-10-26
RU2010130175A (ru) 2012-01-27
US8580968B2 (en) 2013-11-12

Similar Documents

Publication Publication Date Title
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
ATE530519T1 (de) Cyclobutylaminderivate
MY150990A (en) Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands
UA97036C2 (en) Cyclopropyl amine derivatives
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
MX2009005048A (es) Nuevo proceso para la preparacion de derivados de 2-imino-tiazolidin-4-ona.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
UA98772C2 (ru) Производные циклопропиламина как модуляторы н3-гистаминового рецептора
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2009010363A (es) Compuestos de 1,3-tiazol-2(3h)-ilideno como ligandos del receptor canabinoide.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
PL1831202T3 (pl) Pochodne pirolidyniowe jako receptory M3 muskarynowe
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
ME00979B (me) DERIVATI INDOL-2-ONA, DISUPSTITUISANI NA 3-POZICIJI, NJIHOVO DOBIJANJE l PRIMJENA U TERAPIJI
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
MY152069A (en) Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation threof, and therepeutic use thereof
UA94242C2 (ru) Производные бензотиазолциклобутиламина и их применение как лигандов рецепторов гистамина-3
MX2010001600A (es) Nuevo procedimiento de preparacion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal